Investigator's Brochure (IB) Table
Drugs
| Drug Name | Drug Company | IB Date Sort descending | Risk List Available? |
|---|---|---|---|
| HEC Placebo Gel | CONRAD | September 2011 | |
| Tenofovir Gel | CONRAD | January 2013 | |
| Rifapentine | Sanofi | August 2013 | |
| Vorinostat (Zolinza) | Merck | August 2013 | |
| Sofosbuvir/Velapatasvir (Epclusa) | Gilead | July 2016 | |
| Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) | Gilead Sciences | December 2016 | YES |
| PC-1005 | Population Council | April 2017 | |
| Dapivirine (Microbicide Gel) | International Partnership for Microbicides | May 2017 | |
| ABT-267, ABT 333, ABT-450 and Ritonavir | AbbVie | June 2017 | |
| Tenofovir Vaginal Ring | CONRAD | August 2017 | |
| Raltegravir (Isentress) | Merck | September 2017 | YES |
| Maraviroc (UK-427857) | ViiV Healthcare | October 2017 | |
| Etravirine (TMC125, Intelence) | Janssen Research & Development | April 2018 | |
| Dapivirine (Vaginal Ring) | International Partnership For Microbicides | July 2018 | |
| Dolutegravir (GSK1349572) | ViiV Healthcare | November 2018 | |
| Glecaprevir (ABT-493) and Pibrentasvir (ABT-530) - New | AbbVie | December 2018 | |
| GSK1265744 (Cabotegravir) | ViiV Healthcare | December 2018 | |
| Bedaquiline (TMC207) | Janssen Research & Development | February 2019 | |
| Delamanid (OPC-67683) | Otsuka | April 2019 | |
| Doravirine (MK-1439) - New | Merck | May 2019 |
Vaccines
| Vaccine Name | Vaccine Company | IB Date Sort descending | Risk List Available? |
|---|---|---|---|
| GEO-D03 and MVA-HIV62B Vaccines (Preventative) | GeoVax | June 2013 | |
| Ad26.ENVA.01 | Crucell Holland BV | June 2013 | |
| DNA-HIV-PT123/NYVAC-HIV-PT1/NYVAC-HIV-PT4 vaccine | IPPOX/EuroVacc | August 2013 | |
| Bivalent Subtype C gp120 with Aluminum Hydroxide Adjuvant | NIAID/NIH | June 2015 | |
| rVSV HIV Vaccines | Profectus BioSciences | January 2016 | |
| AIDSVAX B/E | Global Solutions for Infectious Diseases | March 2016 | |
| Bivalent Subtype C gp120/AS01B | GlaxoSmithKline | July 2016 | |
| DNA Mosaic-Tre env DNA Vaccine | DAIDS/NIAID/NIH | July 2016 | |
| Bivalent Subtype C gp120/MF59 | GlaxoSmithKline | July 2016 | |
| PENNVAX-GP and IL-12 DNA | Inovio Parmaceuticals | December 2016 | |
| DNA CON-S env | DAIDS/NIAID/NIH | June 2017 | |
| ALVAC-HIV (vCP2438) | Sanofi Pasteur | August 2017 | |
| Recombinant oligomeric gp145 C.6980 Clade C HIV Env protein | NIH/NIAID | August 2017 | |
| VRC-HIVMAB080-00-AB (VRC01LS) | VRC/NIAID | August 2017 | |
| PDPHV-201401 | Laboratory of Nucleic Acid Vaccines (LNAV) | October 2017 | |
| p24CE1/2 multivalent pDNA Vaccine expressing HIV M Group p24 Gag and p55 gag pDNA with IL-12 pDNA | NCI/NIAID/NIH | November 2017 | |
| MVA-CMDR | Walter Reed Army Institute Research (WRAIR) | February 2018 | |
| VRC-HIVMAB075-00-AB (VRC07-523LS) | VRC/NIAID/NIH | February 2018 | |
| SAR441236 | Sanofi | June 2018 | |
| PGDM1400 | Beth Israel Deaconess Medical Center | August 2018 |